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The ABO blood group system, which consists of three main
alleles (two codominant A and B and one recessive O), is
controlled by a single gene located on the terminal portion of
the long armof chromosome 9 (9q34.2).1,2 TheA and B alleles
encode slightly different glycosyltransferases (transferase A,
α 1-3-N-acetylgalactosaminyltransferase; transferase B, α 1-
3-galactosyltransferase) that addN-acetylgalactosamine and
D-galactose, respectively, to a common precursor side chain,
the H substance, converting it into A or B antigens. The O
allele does not encode a functional enzyme and consequently
OO carriers, who lack these transferase enzymes, continue to
express the basic, unmodified H structure constituting a
solitary terminal fucose moiety attached to the precursor
oligosaccharide chain.3
Besides their presence on red blood cells, ABO antigens
are also expressed on the surface of a variety of human cells
and tissues, including epithelial cells, sensory neurons, pla-
telets, and the vascular endothelium.4 It is, therefore, plausi-
ble from a biological point of view that the clinical
significance of ABO blood type may not be limited only to
transfusionmedicine; indeed, there is a large amount of data
from the literature consistently documenting the involve-
ment of ABO blood group antigens in the development of a
wide array of human diseases.5–13 This narrative review will
summarize the main biologic and clinical evidence of the
interaction between hemostasis and ABO blood type focus-
ing on its role in clinical scoring systems assessing throm-
botic risk.
ABO Blood Type and Thrombosis
As previously mentioned, several studies have reported over
the past 50 years the primary relation of ABO blood typewith
thrombosis,14–22 and the recent discovery of the ABO gene as
the most involved locus for both primary and recurrent
venous thromboembolism (VTE) and arterial thrombosis
(i.e., myocardial infarction, coronary artery disease, and
ischemic stroke) has further corroborated this
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Abstract In addition to their major role in transfusion medicine, there is increasing evidence that
ABO blood group antigens (complex carbohydrate molecules widely expressed on the
surface of red blood cells and several other cell types) are implicated in the develop-
ment of a wide array of pathologic conditions. In particular, intense research has been
dedicated over the last 50 years to the study of the association between non-O blood
type and the risk of developing cardiovascular disorders. Several pathways have been
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and several inflammatory cytokines. This narrative review summarizes the current
knowledge on the role of ABO antigens in both venous and arterial thromboses,
focusing on their association with clinical scoring systems evaluating thrombotic risk.
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hypothesis.23–26 Several systematic reviews and meta-anal-
yses have performed pooled analyses of the published stud-
ies with the aim of quantifying the ABO-related residual
thrombotic risk. In a meta-analysis, Wu et al27 reported odds
ratios (ORs) for non-O relative to O blood group of 1.45 (95%
confidence interval [CI], 1.35–1.56) for peripheral vascular
disease, 1.14 (95% CI, 1.01–1.27) for ischemic stroke, 1.25
(95% CI, 1.14–1.36) for myocardial infarction, and 1.79 (95%
CI, 1.56–2.05) for VTE. Anothermeta-analysis, collecting data
from the Health Professionals Follow-up Study, Nurses’
Health Study, and five other prospective cohort studies in
which several thousand participants were enrolled, was
published recently by He et al.28 They concluded that sub-
jects with non-O blood group had a slight but significant
increased relative risk (RR, 1.11; 95% CI, 1.05–1.18;
p < 0.001) of developing coronary heart disease as com-
pared with O blood group individuals. The ABO-associated
venous and arterial thrombotic risk was analyzed separately
by our group in two meta-analyses.29,30 In the first meta-
analysis, which included 38 studies with 10,305 VTE cases,
we noted that having a non-O blood group carries an
approximately twofold increased risk of venous thrombosis
(OR, 2.08; 95% CI, 1.83–2.37).29 In a subsequent systematic
review of 28 studies assessing the association between ABO
blood type and arterial thrombotic events, we found that the
prevalence of non-O blood group was significantly higher in
patients with myocardial infarction (OR, 1.28; 95% CI, 1.17–
1.40; p < 0.001) and ischemic stroke (OR, 1.17; 95% CI, 1.01–
1.35; p ¼ 0.03) than in controls.30 In another meta-analysis
by Takagi and Umemoto31 of 10 studies with a total of
174,945 participants, non-O blood group appeared to be
an independent risk factor for both coronary artery disease
(OR, 1.14; 95% CI, 1.04–1.25; p ¼ 0.006) and myocardial
infarction (OR, 1.16; 95% CI, 1.02–1.31; p ¼ 0.02). An
updated systematic review and meta-analysis by Chen et
al32 combining results from 17 case–control and cohort
studies covering 225,810 participants showed that the risk
of coronary artery disease was significantly higher in blood
group A (OR, 1.14; 95% CI, 1.03–1.26; p ¼ 0.01) and lower in
blood group O (OR, 0.85; 95% CI, 0.78–0.94; p ¼ 0.0008).
Finally, a meta-analysis of 14 genome-wide association
studies of coronary artery disease, including 22,233 cases
and 64,762 controls, identified 23 loci as established risk
factors for coronary artery disease.33 Notably, the authors
identified the rs579459 variant (which tags the A1 allele) in
the ABO locus as having the fifth highest association, with an
OR of 1.10 (95% CI, 1.07–1.13).
The profound influence exerted on hemostasis by ABO
antigens, demonstrated by their close relationship with von
Willebrand factor (VWF) and, consequently, coagulation
factor VIII (FVIII) plasma levels, has been proposed to explain
the association between ABO blood group and thrombotic
vascular disease.34 Indeed, while it has been established that
the ABO system is responsible for approximately 15 and 10%
of overall VWF and FVIII interindividual variability, respec-
tively,35,36 it is equally well known that subjects with non-O
blood group have VWF and FVIII circulating levels that are
approximately 25%higher thanObloodgroup subjects.33 The
presence of ABO blood group determinants on VWF
N-glycans provides the molecular basis of the connection
between ABO blood group and VWF levels.34 In individuals
with O blood group, VWF is cleaved by ADAMTS13
(a disintegrin andmetalloproteinasewith a thrombospondin
type 1motif,member 13) and undergoes enhanced clearance
through low-density lipoprotein receptor-related protein 1
(LRP1), resulting in a reduced VWF activity compared with
those with non-O blood group. Conversely, in individuals
with non-O blood group, the A/B/AB antigen-related VWF
glycosylation protects it from proteolysis and clearance by
ADAMTS13 and LRP1, respectively, resulting in increased
VWF levels compared with those with O blood group.37–39
Beyond the associationwith levels of circulating VWF, recent
investigations have been focused on the capacity of ABO
blood group antigens to influence serum levels of several
inflammatory cytokines (i.e., tumor necrosis factor-α, solu-
ble intercellular adhesion molecule 1, E-selectin, P-selectin,
and interleukin 6), whose higher concentrations have been
associated with an increased risk of cardiovascular throm-
botic events.40–43 Finally, the observations of the association
between the ABO locus and plasma lipoprotein concentra-
tions44 and between non-O blood types and increased
circulating cholesterol levels45,46 add another important
contribution to the understanding of the pathogenic mech-
anisms underlying the correlation between ABO blood group
and coronary heart disease susceptibility. All in all, these
data document that the relation between the ABO blood
group system and cardiovascular diseases is more complex
than the simple modulation of hemostasis.
Interaction between ABO Blood Type and
Other Thrombotic Risk Factors
Besides the consistent experimental and clinical observations
of the close relationship between ABO blood group and
thrombotic vascular disease, several studies have also investi-
gated the interaction between ABO antigens and other known
thrombotic risk factors.20,47–52 In the Longitudinal Investiga-
tion of Thromboembolism Etiology (LITE) study,49 which
analyzed the ABO genotype in 492 participants who subse-
quently developed VTE and 1,008 participants who remained
free of VTE, the authors observed that the VTE risk in non-O
blood type individuals increasedmore than fivefold (ORs from
1.31 [95% CI, 1.02–1.68] to 6.77 [95% CI, 3.65–12.6])when they
were also carriers of factor V (FV) Leiden. The fact that the
combination of FV Leiden and non-O blood typewas associat-
ed with VTE more strongly than expected from a simple
additive model of individual risks was confirmed in further
studies. For instance, in a Danish case cohort study51 of 56,104
participants with 641 incident VTE episodes, the presence of
FV Leiden heterozygosity conferred a hazard ratio (HR) for VTE
of 2.84 (95% CI, 2.15–3.76), but when present in persons with
non-O blood type, the adjusted HR for VTE became 5.12
(95% CI, 3.05–8.59), exceeding the sum of separate effects. In
a retrospective case–control studyconducted in Italyona large
number of patients with deep vein thrombosis (DVT) and
controls (712 cases and 712 controls), the investigators found
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that the non-O bloodgroup increased the riskof DVT 2.2 times
(OR, 2.21; 95% CI, 1.78–2.75) over groupO. A sevenfold greater
increase in the DVT risk (OR, 7.06; 95% CI, 4.85–10.28) was
observed when an inherited thrombophilic condition (FV
Leiden, prothrombin G20210Amutation, deficiencies of natu-
ral anticoagulants) was combined with non-O group.20 Per-
taining to the pooled analyses of data, the synergistic effect on
VTE risk of the association between non-O status and FV
Leiden observed in the meta-analysis by Wu et al27 (OR,
7.60; 95% CI, 3.21–17.99) was subsequently replicated in the
meta-analysis performed by our group29 (OR, 3.88; 95% CI,
2.51–6.00). In addition to the interaction with inherited
thrombophilic risk factors, there are also increasing amounts
of data documenting a synergistic hypercoagulable effect of
ABO blood group antigens in several physiological or clinical
conditions characterized by increased thrombotic potential,
such as pregnancy and the puerperium, postmenopausal
hormone replacement therapy, trauma, and cancers.53–57
The main results of the most important studies assessing
the link between ABO blood type and inherited and/or ac-
quired thrombotic conditions are summarized in ►Table 1.
ABO Blood Type and Cardiovascular Scoring
Systems
As previously described, there is a large body of evidence
consistently demonstrating that ABO blood type is not only
an important genetic determinant of venous and arterial
thromboses but it is also able to interact with other genetic
and nongenetic factors in the modulation of thrombotic risk.
As a result, with the aim of better quantifying the ABO
attributable thrombotic risk, some investigators have as-
sessed the association of ABO blood group with scores
evaluating arterial thrombotic risk. Yang et al58 investigated
ABO blood group in 1,311 young Chinese adults with acute
ischemic cerebral stroke by using the National Institutes of
Health Stroke Scale (NIHSS) score, a valid, reliable, and
reproducible neurological severity scale performed at ad-
mission and associated with chronic functional outcome.
Notably, the authors demonstrated the utility of the score as
a predictor of clinical outcomes in ABO blood group, since
stroke patients with non-O blood group have a higher
probability of an unfavorable outcome at discharge than O
blood type patients with the same NIHSS scores. In addition,
Gong et al59 investigated the relation of ABO blood type and
the severity of coronary atherosclerosis assessed by the
Gensini score, a useful angiographic system to assess fatal
and nonfatal cardiovascular events. The results of this large
Chinese cohort study, which enrolled 2,919 consecutive
patients undergoing coronary angiography, showed that
while blood group A was an independent risk factor
(OR, 1.44; 95% CI, 1.16–1.80; p ¼ 0.001), group O was a
protective factor (OR, 0.77; 95% CI, 0.65–0.92; p ¼ 0.004)
for serious coronary atherosclerosis. Finally, the relationship
Table 1 Characteristics of the main studies on the association between ABO blood group and other thrombotic risk factors
First author (year)ref. Study design Cases/controls Non-O vs. O blood group-associated
thrombotic risk
Morelli (2005)48 Case–control 471 with VTE/471 without VTE OR, 1.7 (95% CI, 1.3–2.3)
FVL carriers: OR, 23.2 (95% CI, 9.1–59.3)a
Ohira (2007)49 Case–control 492 with VTE/1,008 without VTE aOR, 1.31 (95% CI, 1.01–1.68)
FVL carriers: aOR, 6.77 (95% CI, 3.65–12.6)
Miñano (2008)50 Case–control 807 FVL/PT 20210A carriers:
609 with VTE/198 without VTE
FVL carriers: OR, 1.76 (95% CI, 1.06–2.91)
PT 20210A carriers: OR, 2.17
(95% CI, 1.33–3.53)
El-Galaly (2012)51 Case–control 578 with VTE/1,733 without VTE aHR, 1.84 (95% CI, 1.50–2.27)
FVL carriers: aHR, 5.12 (95% CI, 3.05–8.59)
Spiezia (2013)20 Case–control 712 with DVT/712 without DVT OR, 2.21 (95% CI, 1.78–2.75)
FVL carriers: OR, 3.67 (95% CI, 2.45–5.48)
Sode (2013)52 Prospective 66,001 participants with 2,279 VTE aHR, 1.4 (95% CI, 1.3–1.5)
FVL carriers: aHR, 2.2 (95% CI, 2.0–2.2)
Streiff (2004)54 Retrospective 28 with VTE/102 without VTEb A vs. O: HR, 2.7 (95% CI, 1.0–7.0)
AB vs. O: HR, 9.4 (95% CI, 2.7–32)
Larsen (2005)55 Case–control 129 with VTE/258 without VTEc A vs. O: aOR, 2.4 (95% CI, 1.3–4.3)
AB vs. O: aOR, 2.0 (95% CI, 0.7–5.8)
Canonico (2008)56 Case–control 271 with VTE/610 without VTEd aOR, 8.9 (95% CI, 4.4–17.8)e
Abbreviations: aHR, adjusted hazard ratio; aOR, adjusted odds ratio; CI, confidence interval; DVT, deep vein thrombosis; FVL, factor V Leiden; OR,
odds ratio; PT, prothrombin; VTE, venous thromboembolism.
aVersus O blood group and FVL ().
bPatients with malignant glioma.
cWomen during pregnancy or puerperium.
dWomen under postmenopausal hormone therapy.
eNon-O oral estrogen users versus O nonusers.
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between ABO blood type and cardiovascular disease was
assessed by our group using the Cardiorisk score.60 During
the decade 2005 to 2015, 17,197 Italian blood donors were
enrolled in the Cardiorisk program, derived from the Fra-
mingham risk profile algorithm,61 which included the as-
sessment of eight variables (sex, age, total cholesterol, high-
density lipoprotein cholesterol, glycemia, arterial blood
pressure, antihypertensive therapy, and smoking) which
were used to generate a score. The 249 individuals with a
resulting score  20, considered at high cardiovascular risk,
underwent additional tests (chest X-ray, stress electrocar-
diogram, andDoppler ultrasound of supra-aortic trunks) and
were closely monitored clinically for at least 2 years of
follow-up. Among these, 36 (14.5%) had abnormal tests
and 23 of them developed adverse cardiovascular events
(10 acute coronary syndrome, 2 cerebral ischemia, 3 cardiac
arrhythmia, 8 stenosis of supra-aortic trunks or iliac arteries)
during a median follow-up of 5.3 years. A subanalysis of ABO
blood group in this cohort of 249 high-risk individuals found
a statistically significant association between the non-O
blood type and the risk of developing subclinical or clinical
cardiovascular events (OR, 3.3; 95% CI, 1.1–10.1).
Conclusion
Overall, a large body of evidence from experimental and
clinical studies documents the close link between the ABO
blood group system and hemostasis, and several lines of
research indicate that ABO blood group antigens might
modulate various distinct pathways related to cardiovascular
risk factors, atherosclerosis, and thrombosis. Thanks to in-
tense research in this field, today, it is possible to conclude
that non-O blood type is an independent risk factor for both
venous and arterial thromboses. In addition, investigation of
the association between ABO antigens and traditional car-
diovascular risk factors in the context of thrombotic score
assessments has identified non-O blood type as an important
cardiovascular prognostic biomarker. However, research in
this field is in its early stages and further studies are needed
to better clarify the interaction of the ABO antigens with
other acquired and inherited thrombotic risk factors. In
particular, considering that non-O blood type is associated
with an approximately twofold increased VTE risk, it could
be very interesting to analyze its relation with scores assess-
ing the risk of primary and recurrent vein thrombosis.62
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